drug · intermediate · partly written
Patisiran (Onpattro)
Patisiran is an siRNA against transthyretin mRNA, packed in a lipid nanoparticle and given by intravenous infusion, which slowed nerve damage in hereditary transthyretin amyloidosis.
Also called: Onpattro
This describes published medicine for readers who want to understand how it works and what happened. It is not medical advice and says nothing about what any person should take.
The short version
Patisiran switches off much of the liver's production of transthyretin by sending a matching RNA into liver cells. In the 225-patient APOLLO trial, nerve damage scores rose 28.0 points on placebo and fell 6.0 on the drug at 18 months. A fat particle gets the RNA in. Infusion reactions and low vitamin A are the costs. 12
Reported, not yet replicated
The decisive trial more
APOLLO was a phase 3 trial in hereditary transthyretin amyloidosis with polyneuropathy. Patients were randomised 2:1 (148 to patisiran, 77 to placebo) to 0.3 mg per kilogram intravenously every 3 weeks. The primary end point was the change in the modified Neuropathy Impairment Score+7 (mNIS+7, range 0 to 304, higher is worse) at 18 months: -6.0 versus +28.0, a difference of -34.0 points (P<0.001). The Norfolk quality-of-life score changed by -6.7 versus +14.4 (difference -21.1, P<0.001). Gait speed changed by +0.08 versus -0.24 metres per second. Read from the abstract; the full paper was not opened here. The trial was funded by the developer. 1
Reported, not yet replicated
What the numbers mean more
On placebo the disease got worse by 28 points; on patisiran the score barely moved, improving slightly. The 34-point gap is driven by that contrast, so the result is best read as slowing or halting progression. The label reports serum TTR down about 80 percent within 10 to 14 days of a single dose and 84 percent at 18 months, which shows the mechanism engaged, but the trial's claim rests on the nerve and quality-of-life measures, not on the knockdown. 12
Reported, not yet replicated
How it gets to the liver more
The particle is a lipid nanoparticle. Per the label it is formulated as a lipid complex for delivery to liver cells. The general account is that blood apolipoprotein E coats the particle and liver cells take it up; the paper behind that account found that without apolipoprotein E in mice the liver effect of an ionisable particle was essentially abolished. See the lipid nanoparticle record for what is and is not known about the later steps. 23
Reported, not yet replicated
Why one infusion lasts weeks deep
The label gives a terminal half-life of 3.2 +/- 1.8 days, yet the drug is given every 3 weeks, so the effect on TTR is not tracking the drug level in blood. That the knockdown outlasts the drug in plasma is our inference from these two label facts, not something the label states. Why it outlasts it (an intracellular store, a long-lived silencing complex) was not established from a source opened for this record. 2
Our inference
What the approval and the label say deep
The company announced US approval on 10 August 2018; that date is a company statement. The European authorisation is for adults with stage 1 or stage 2 polyneuropathy. Whether the drug helps heart disease from the same amyloid was not established from a primary source opened for this record. 45
Reported, not yet replicated
Where it is limited deep
APOLLO tested one population: people with nerve disease. The result is not evidence about people with advanced heart disease from transthyretin amyloid, where the sibling drug revusiran was stopped (see its record). Infusion reactions need premedication, and whether people make antibodies to the PEG on the particle is an open question in the atlas. 156
Reported, not yet replicated
Modality
Targets
Pathways
Indications
Identifiers
Clinicaltrials gov pivotal
NCT01960348
Trial name
APOLLO
Mechanism
The drug is a short double-stranded RNA matching the transthyretin messenger RNA. The label says it causes degradation of mutant and wild-type TTR mRNA through RNA interference, so the liver makes less TTR protein and less is available to form amyloid around nerves. The cell's own silencing machinery does the cutting; the drug supplies the address. 21
Reported, not yet replicated
Delivery route
Must survive
A bare RNA this size and charge cannot cross a cell membrane, so the drug is a lipid complex of the siRNA with four lipids (an ionisable lipid, cholesterol, a phospholipid and a PEG-lipid). The label reports that more than 95 percent of circulating drug is lipid-associated and that it distributes mainly to the liver. It must stay intact in blood, reach liver cells and release the RNA inside them; patients receive premedication to reduce infusion reactions. 253
Reported, not yet replicated
Side effects
Infusion-related reactions
Reported in 19 percent of patisiran patients versus 9 percent on placebo in the label, despite required premedication (steroid, acetaminophen, antihistamines). The trial abstract gives about 20 versus 10 percent, mild or moderate. The European summary lists them among the effects affecting more than 1 in 10 people. 215
Reported, not yet replicated
Peripheral oedema
Listed on the European summary page among the effects affecting more than 1 in 10 people; no separate frequency is given there. 5
Reported, not yet replicated
Lower vitamin A (on-target)
Transthyretin carries retinol-binding protein, which carries vitamin A. The label reports serum retinol-binding protein down 45 percent and serum vitamin A down 62 percent over 18 months, and advises vitamin A supplementation at the recommended daily allowance. 25
Reported, not yet replicated
Verdict
Outcome
worked
Why
In APOLLO (225 patients, 18 months) the neuropathy score worsened by 28.0 points on placebo and changed by -6.0 on patisiran, a difference of -34.0 points (P<0.001). Quality of life, gait speed and a nutrition measure also favoured the drug. The target is made in the liver, the particle goes to the liver, and a clinical measure moved within 18 months. It reads as halting progression more than reversing it. 1
Reported, not yet replicated
Teach this
In one sentence
Patisiran is a piece of RNA wrapped in fat that tells liver cells to make less transthyretin, and in a 225-patient trial it stopped nerve damage getting worse. 1
Reported, not yet replicated
The five-minute version
Transthyretin made in the liver misfolds and deposits around nerves. Patisiran is a short RNA duplex that guides the cell's own silencing machinery to cut the transthyretin message. Because RNA cannot enter cells alone, it travels in a lipid particle that reaches the liver. In APOLLO the neuropathy score rose 28.0 on placebo and fell 6.0 on the drug at 18 months. Costs: infusion reactions requiring premedication, swelling, and lower vitamin A because transthyretin carries it. 125
Reported, not yet replicated
What a listener will ask
Does it edit the gene?
No. It acts on the messenger RNA, so the gene is untouched and the effect depends on continued dosing; the label gives a half-life of days and dosing every 3 weeks. 2
Reported, not yet replicated
Why not a pill?
The RNA is large and heavily charged, so it cannot cross membranes on its own; the label describes a lipid complex given by infusion. 2
Reported, not yet replicated
Is lowering the protein enough to prove it works?
No. The approval rests on nerve and quality-of-life measures in APOLLO, not on knockdown alone. 1
Reported, not yet replicated
The common wrong idea
A drug that switches off its target gene is risk-free because it only does what it was designed to do.
Lowering transthyretin also lowers the vitamin A it carries, so the label advises supplementation; a clean target can still have an on-target cost. 2
Reported, not yet replicated
The one citation to hand over: 1
Still open here
- Primary sources for the US approval details and for any later regulatory decision on heart disease were not opened for this record.
- Why the effect on TTR outlasts the drug in blood: no primary source was opened.
- Whether people make antibodies to the PEG on the particle, and what that does: see questions/anti-peg-antibody-responses.
- The full APOLLO paper and its supplementary data were not read.
Not yet written: Assays used, Off targets.
Linked from
Sources
- Adams D, et al.. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med (2018). paper; opened 2026-11-17 all records citing this
- Onpattro (patisiran) lipid complex injection US prescribing information. Alnylam Pharmaceuticals (2025). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
- Akinc A, Querbes W, De S, Qin J, et al.. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther (2010). paper; opened 2026-11-17 all records citing this
- FDA approves ONPATTRO (patisiran), announced 10 August 2018. Alnylam Pharmaceuticals investor relations (2018). organisation-page, not peer reviewed; opened 2026-11-17 all records citing this
- Onpattro: EPAR summary page. European Medicines Agency (2026). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
- Judge DP, et al.. Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovasc Drugs Ther (2020). paper; opened 2026-11-17 all records citing this
Where it sits on the map
History of this record (5)
This record has been changed 5 times, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.
- Year
- 2018
- Regulatory status
- approved
- Status
- partly written
- Last updated
- 2026-11-19
- Record
- content/drugs/patisiran.json